News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Release: Data Demonstrates Key Genes Respond Differently To COPAXONE┬« (glatiramer acetate injection) Versus A Purported Generic Glatiramer Acetate



1/13/2014 10:49:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) today announced the publication of data that demonstrates significant differences in biological and immunological effects between COPAXONE® (glatiramer acetate, GA) and a purported generic glatiramer acetate (GA), marketed in India, (Glatiramer®, Natco Pharma, Ltd., Hyderabad, India), with potential clinical ramifications.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES